SSgA Funds Management, Inc. recently announced the acquisition of new stake in Pfizer Inc. (NYSE:PFE). The institutional investor has increased its shareholding in the Healthcare company by 2.15% to 298.9 million shares with purchase of 6.28 million shares. This fresh investment now brings its stake to 5.38% valued currently at $11.5 billion. In addition, BlackRock Fund Advisors raised its holdings by 9.49 million to 279.95 million shares. And Wellington Management Co. LLP has lifted its position by 14.72% or 32.18 million shares – to 250.85 million shares.

With over 28.45 million Pfizer Inc. (PFE) shares trading Monday and a closing price of $37.79 on the day, the dollar volume was approximately $1.08 billion. The shares have shown a negative weekly performance of -2.70% and its price on 08/31/20 lost nearly -0.32%. Currently, there are 5.55B common shares owned by the public and among those 5.55B shares have been available to trade.

An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 16 analysts who have offered their price forecasts for PFE have a consensus price objective of $41.69. The analysts have set the share’s price value over the next 12 months at a high of $53.00 and a low of $35.00 should the stock experience a downside. Incidentally, analysts’ outlook for the Pfizer Inc. stock is 2.50 for the next 12 months. The average price target is 9.57% above its last price level and an upside to the estimated low will see the stock lose -7.97% over that period. But an upside of 28.7% will see the stock hit the forecast high price target while mean target price for the stock is $42.00.

Insiders at the company have transacted a total of 113 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 37 of these insider trades were purchases, accounting for 1,469,796 shares. Insider sales of the common stock occurred on 76 occasions, with total insider shares sold totaling 1,359,096 shares.

The top 3 mutual fund holders in Pfizer Inc. are Vanguard Total Stock Market Index, Vanguard 500 Index Fund, and Washington Mutual Investors Fund. Vanguard Total Stock Market Index owns 157.91 million shares of the company’s stock, all valued at over $6.08 billion. The company sold -0.44 million shares recently to bring their total holdings to about 2.84% of the shares outstanding. Vanguard 500 Index Fund sold -0.7 million shares to see its total holdings shrink to 114.55 million shares valued at over $4.41 billion and representing 2.06% of the shares outstanding. Washington Mutual Investors Fund bought 9.63 million shares to bring its total holdings to over 75.96 million shares at a value of $2.92 billion. Washington Mutual Investors Fund now owns shares totaling to 1.37% of the shares outstanding.

Shares of Pfizer Inc. (NYSE: PFE) opened at $37.84, down -$0.07 from a prior closing price of $37.91. However, the script later closed the day at $37.79, down -0.32%. The company’s stock has a 5-day price change of -2.70% and 4.51% over the past three months. PFE shares are trading -3.55% year to date (YTD), with the 12-month market performance up to 6.30% higher. It has a 12-month low price of $27.88 and touched a high of $40.97 over the same period. Currently, 28.45 million shares have been traded, compared to an average intraday trading volume of 31.01 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -1.37%, 3.58%, and 3.37% respectively.

Institutional ownership of Pfizer Inc. (NYSE: PFE) shares accounts for 72.00% of the company’s 5.55B shares outstanding. Mutual fund holders own 32.17%, while other institutional holders and individual stakeholders account for 39.74% and 0.29% respectively.

It has a market capitalization of $209.72B and a beta (3y monthly) value of 0.66. The stock’s trailing 12-month PE ratio is 15.38, while the earnings-per-share (ttm) stands at $2.46. The company has a PEG of 2.87 and a Quick Ratio of 1.20 with the debt-to-equity ratio at 0.99. Price movements for the stock have been influenced by the stock’s volatility, which stands at 1.45% over the week and 1.40% over the month.

Analysts forecast that Pfizer Inc. (PFE) will achieve an EPS of $0.71 for the current quarter, $0.63 for the next quarter and $3.34 for 2021. The lowest estimate earnings-per-share for the quarter is $0.6 while analysts give the company a high EPS estimate of $0.79. Comparatively, EPS for the current quarter was $0.75 a year ago. Earnings per share for the fiscal year are expected to increase by 62.30%, and 13.92% over the next financial year. EPS should shrink at an annualized rate of 5.37% over the next five years, compared to 14.70% over the past 5-year period.

If you are looking to buy this stock, then you may note that the average analyst recommendation by 16 brokerage firm advisors rate Pfizer Inc. (PFE) as a “Moderate Buy” at a consensus score of 2.50. Specifically, 6 Wall Street analysts polled rate the stock as a buy, while 8 of the 16 advise that investors “hold,” and 0 rated it as a “Sell.”

Looking at the support for the PFE, a number of firms have released research notes about the stock. SVB Leerink stated their Mkt Perform rating for the stock in a research note on June 16, 2020, with the firm’s price target at $40. Standpoint Research coverage for the Pfizer Inc. (PFE) stock in a research note released on February 27, 2020 offered a Buy rating with a price target of. Barclays was of a view on February 27, 2020 that the stock is Equal Weight, while Mizuho gave the stock Buy rating on February 06, 2020, issuing a price target of. RBC Capital Mkts on their part issued Outperform rating on January 07, 2020.